Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 426

1.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

2.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
3.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H, Begg CB, Berwick M.

J Clin Oncol. 2013 Nov 20;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. Epub 2013 Oct 14.

4.

Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso AP, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone A.

Oncotarget. 2015 Aug 14;6(23):19868-79.

5.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

PMID:
21343559
6.

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.

Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C.

BMC Cancer. 2017 Aug 10;17(1):536. doi: 10.1186/s12885-017-3529-5.

7.

Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.

Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA.

Cancer Causes Control. 2014 Oct;25(10):1379-86. doi: 10.1007/s10552-014-0443-x. Epub 2014 Jul 22.

8.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2014 Jun 15;20(12):3328-37. doi: 10.1158/1078-0432.CCR-14-0093. Epub 2014 Apr 8.

9.

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F.

Hum Pathol. 2016 Nov;57:116-125. doi: 10.1016/j.humpath.2016.07.008. Epub 2016 Jul 26. Erratum in: Hum Pathol. 2017 May;63:222.

10.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

11.

Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Xu S, Yang Z, Zhang J, Jiang Y, Chen Y, Li H, Liu X, Xu D, Chen Y, Yang Y, Zhang Y, Li D, Xia J.

DNA Cell Biol. 2015 Jan;34(1):69-77. doi: 10.1089/dna.2014.2590.

12.

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.

Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, Ogata D, Matsushita S, Fujii K, Fukushima S, Shibayama Y, Hatta N, Takenouchi T, Uehara J, Okuyama R, Yamazaki N, Uhara H.

J Dermatol Sci. 2015 Oct;80(1):33-7. doi: 10.1016/j.jdermsci.2015.07.012. Epub 2015 Jul 26.

PMID:
26282084
13.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

14.

Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.

Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenović S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA, Eggermont AM, Rutkowski P.

Ann Surg Oncol. 2014 Dec;21(13):4317-23. doi: 10.1245/s10434-014-3799-y. Epub 2014 May 28.

15.

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J.

J Dermatol Sci. 2013 Dec;72(3):284-9. doi: 10.1016/j.jdermsci.2013.07.013. Epub 2013 Aug 8.

PMID:
23993026
16.

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.

Egberts F, Bergner I, Krüger S, Haag J, Behrens HM, Hauschild A, Röcken C.

Ann Oncol. 2014 Jan;25(1):246-50. doi: 10.1093/annonc/mdt411. Epub 2013 Nov 24.

PMID:
24276025
17.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

18.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.

Eur J Cancer. 2014 Oct;50(15):2668-76. doi: 10.1016/j.ejca.2014.06.009. Epub 2014 Jul 25.

PMID:
25070294
19.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2.

20.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

Supplemental Content

Support Center